Canopy Growth (CGC) Other Non-Current Liabilities (2017 - 2026)
Canopy Growth (CGC) posted Other Non-Current Liabilities of $27.3 million for Q1 2026, up 244.31% sequentially from $7.9 million in Q4 2025, and up 7.81% YoY from $25.3 million in Q1 2025.
Canopy Growth (CGC) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Canopy Growth has reported Other Non-Current Liabilities for 10 years, with the latest figure at $27.3 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 7.81% year-over-year to $27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.3 million (up 7.81% YoY) and the FY2026 annual result came in at $27.3 million, up 7.81% from the prior year.
- Other Non-Current Liabilities advanced to $27.3 million in Q1 2026 per CGC's latest filing, from $7.9 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $73.4 million in Q2 2023 and troughed at $529821.7 in Q3 2022.
- A 5-year average of $25.4 million and a median of $22.6 million in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities plunged 99.37% in 2022, then jumped 2808.56% in 2023.
- Over 5 years, Other Non-Current Liabilities stood at $29.4 million in 2022, then tumbled by 76.19% to $7.0 million in 2023, then soared by 242.51% to $24.0 million in 2024, then plunged by 66.97% to $7.9 million in 2025, then soared by 244.31% to $27.3 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $27.3 million, $7.9 million, and $11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Canopy Growth | 437.04 Mn | 190.03 Mn | 16.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.14 Mn |
| Mar 31, 2026 | 27.25 Mn |
| Dec 31, 2025 | 7.92 Mn |
| Sep 30, 2025 | 11.13 Mn |
| Jun 30, 2025 | 8.65 Mn |
| Mar 31, 2025 | 25.28 Mn |
| Dec 31, 2024 | 23.97 Mn |
| Sep 30, 2024 | 33.25 Mn |
| Jun 30, 2024 | 48.11 Mn |
| Mar 31, 2024 | 53.29 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Sep 30, 2023 | 15.41 Mn |
| Jun 30, 2023 | 73.36 Mn |
| Dec 31, 2022 | 29.39 Mn |
| Sep 30, 2022 | 529,821.66 |
| Jun 30, 2022 | 20.86 Mn |
| Mar 31, 2022 | 21.25 Mn |
| Dec 31, 2021 | 155.19 Mn |
| Sep 30, 2021 | 84.06 Mn |
| Jun 30, 2021 | 88.71 Mn |